<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111977</url>
  </required_header>
  <id_info>
    <org_study_id>R01MH127225</org_study_id>
    <nct_id>NCT05111977</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Interoception in Anorexia Nervosa</brief_title>
  <official_title>A Neurocomputational Assay of Gastrointestinal Interoception in Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laureate Institute for Brain Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laureate Institute for Brain Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anorexia nervosa (AN) has among the highest mortality rate of any psychiatric illness, yet we&#xD;
      have a poor understanding of the biological causes of this disorder. In this study, we use a&#xD;
      novel mechanosensory intervention to examine the basic question of whether individuals with&#xD;
      AN have abnormal &quot;gut sensations&quot; and whether such indicators are associated with adverse&#xD;
      consequences from the disorder.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">April 2026</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interoceptive precision</measure>
    <time_frame>At baseline</time_frame>
    <description>Interoceptive sensory precision</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interoceptive prior</measure>
    <time_frame>At baseline</time_frame>
    <description>Interoceptive prior expectaiton</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Learning rate</measure>
    <time_frame>At baseline</time_frame>
    <description>Interoceptive learning rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evoked response potential</measure>
    <time_frame>At baseline</time_frame>
    <description>Electroencephalogram (EEG) evoked response amplitude within 700 millisecond period following vibration onset</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrogastrogram</measure>
    <time_frame>At baseline</time_frame>
    <description>Stomach electrogastrogram (EGG) power in bradygastria, normogastria, tachygastria and total power bands</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normalized A prime</measure>
    <time_frame>At baseline</time_frame>
    <description>Signal detection accuracy measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illness status</measure>
    <time_frame>At 1 month, 3 month, and 6 month follow-up</time_frame>
    <description>Relapse, remission, or recovery status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Anorexia Nervosa</condition>
  <arm_group>
    <arm_group_label>Capsule stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive gastric stimulation via the Vibrant capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive no gastric stimulation via a placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibrant capsule</intervention_name>
    <description>A capsule delivering mechanical vibrations</description>
    <arm_group_label>Capsule stimulation</arm_group_label>
    <arm_group_label>Placebo stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        HC Inclusion criteria:&#xD;
&#xD;
        i. Body mass index ≥ 18.5. ii. Females, ages 15 to 40 years iii. Women of childbearing age:&#xD;
        a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a&#xD;
        double-barrier method of birth control must be used throughout the study.&#xD;
&#xD;
        iv. Independently ambulatory v. Possession of a smartphone with data plan vi. English&#xD;
        proficiency vii. Willingness and ability to participate in study procedures viii. Provision&#xD;
        of signed and dated informed consent form&#xD;
&#xD;
        AN Inclusion criteria:&#xD;
&#xD;
        i. Primary clinical diagnosis of anorexia nervosa as defined by Laureate Eating Disorders&#xD;
        Program ii. Body mass index ≥ 18.5. iii. Transitioned from acute clinical status rating to&#xD;
        residential clinical status or partial/intensive outpatient clinical status rating iv. No&#xD;
        new medication prescription in the week prior to study randomization, Must be on a stable&#xD;
        dose of medication for at least 1 week.&#xD;
&#xD;
        v. Females, ages 15 to 40 years vi. Women of childbearing age: a hormonal (i.e., oral,&#xD;
        implantable, or injectable) and single-barrier method, or a double-barrier method of birth&#xD;
        control must be used throughout the study.&#xD;
&#xD;
        vii. Independently ambulatory viii. Possession of a smartphone with data plan ix. English&#xD;
        proficiency x. Willingness and ability to participate in study procedures xi. Provision of&#xD;
        signed and dated informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        HC Exclusion criteria:&#xD;
&#xD;
        i. Current diagnosis of a psychiatric disorder per the MINI International Diagnostic&#xD;
        Interview&#xD;
&#xD;
        ii. Taking any psychotropic medication&#xD;
&#xD;
        iii. Active suicidal ideation with intent or plan&#xD;
&#xD;
        iv. Active cutting or skin lacerating behaviors&#xD;
&#xD;
        v. Active purging behaviors (specifically, self-induced vomiting), and/or a history of&#xD;
        severe self-induced vomiting&#xD;
&#xD;
        vi. Pregnancy as defined by a urine screen during screening, and confirmed during each&#xD;
        stimulation visit, and must not be lactating&#xD;
&#xD;
        vii. History of significant gastrointestinal disorder, including any form of inflammatory&#xD;
        bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has&#xD;
        been treated and is in remission)&#xD;
&#xD;
        viii. History of complicated/obstructive diverticular disease&#xD;
&#xD;
        ix. Clinical evidence of significant gastroparesis&#xD;
&#xD;
        x. Diagnosis of mega-rectum or colon, congenital anorectal malformation, or clinically&#xD;
        significant rectocele or rectal prolapse&#xD;
&#xD;
        xi. History of intestinal or colonic obstruction, or suspected intestinal obstruction&#xD;
&#xD;
        xii. History of intestinal resection (with an exception for appendectomy, cholecystectomy&#xD;
        and inguinal hernia repair), history of bariatric surgery or evidence of any structural&#xD;
        abnormality of the gastrointestinal tract that might affect transit&#xD;
&#xD;
        xiii. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal&#xD;
        stricture or achalasia, transesophageal fistula, or eosinophilic esophagitis.&#xD;
&#xD;
        xiv. Clinical evidence (as judged by the investigator) of respiratory, cardiovascular,&#xD;
        renal, hepatic, biliary, endocrine, or neurologic disease&#xD;
&#xD;
        xv. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined&#xD;
        as taking full dose NSAIDs more than three times a week for at least six months. Subjects&#xD;
        on cardiac doses of aspirin may be enrolled in the study&#xD;
&#xD;
        xvi. Cardiac pacemaker, implantable cardioverter defibrillator, implantable infusion&#xD;
        device, or gastric electrical stimulator&#xD;
&#xD;
        xxv. Orthostatic hypotension (defined as a drop of ≥ 20 mm Hg in systolic BP or a drop of ≥&#xD;
        10 mm Hg in diastolic BP when measured shortly after transitioning from lying down to&#xD;
        standing)&#xD;
&#xD;
        xxvi. Any other condition which in the opinion of the investigator may adversely affect the&#xD;
        safety of the subject or would limit the subject's ability to complete the study&#xD;
&#xD;
        xxvii. No smartphone/computer or limited access to a smartphone/computer&#xD;
&#xD;
        xxviii. Regular use of any of the following medications or procedures: Medications that may&#xD;
        substantially affect intestinal motility, prokinetics at high doses (metoclopramide,&#xD;
        erythromycin, senna, prucalopride), anti-Parkinsonian medications, opiates, opioids,&#xD;
        calcium-channel blockers, enemas&#xD;
&#xD;
        xxix. History of a GI bleed within the last 3 months&#xD;
&#xD;
        xxx. Pelvic floor dysfunction/defecatory disorder, based on subject history&#xD;
&#xD;
        xxxi. Planning to undergo MRI during study time frame&#xD;
&#xD;
        xxxii. Any known allergy to soybean or beeswax or Calcium Carbonate&#xD;
&#xD;
        xxxiii. Bradycardia less than 40 beats per minute&#xD;
&#xD;
        xxxiv. Pain Disorder&#xD;
&#xD;
        AN Exclusion criteria:&#xD;
&#xD;
        i. Active suicidal ideation with intent or plan&#xD;
&#xD;
        ii. Active cutting or skin lacerating behaviors&#xD;
&#xD;
        iii. Active purging behviors (specifically, self-induced vomiting), and/or a history of&#xD;
        severe self-induced vomiting&#xD;
&#xD;
        iv. Pregnancy as defined by a urine screen during screening, and confirmed during each&#xD;
        stimulation visit, and must not be lactating&#xD;
&#xD;
        v. History of significant gastrointestinal disorder, including any form of inflammatory&#xD;
        bowel disease or gastrointestinal malignancy (celiac disease is accepted if the subject has&#xD;
        been treated and is in remission)&#xD;
&#xD;
        vi. History of complicated/obstructive diverticular disease&#xD;
&#xD;
        vii. Clinical evidence of significant gastroparesis&#xD;
&#xD;
        viii. Diagnosis of mega-rectum or colon, congenital anorectal malformation, or clinically&#xD;
        significant rectocele or rectal prolapse&#xD;
&#xD;
        ix. History of intestinal or colonic obstruction, or suspected intestinal obstruction&#xD;
&#xD;
        x. History of intestinal resection (with an exception for appendectomy, cholecystectomy and&#xD;
        inguinal hernia repair), history of bariatric surgery or evidence of any structural&#xD;
        abnormality of the gastrointestinal tract that might affect transit&#xD;
&#xD;
        xi. History of Zenker's diverticulum, dysphagia, Barrett's esophagus, esophageal stricture&#xD;
        or achalasia, transesophageal fistula, or eosinophilic esophagitis.&#xD;
&#xD;
        xii. Clinical evidence (as judged by the investigator) of respiratory, cardiovascular,&#xD;
        renal, hepatic, biliary, endocrine, or neurologic disease&#xD;
&#xD;
        xiii. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs): chronic use is defined&#xD;
        as taking full dose NSAIDs more than three times a week for at least six months. Subjects&#xD;
        on cardiac doses of aspirin may be enrolled in the study&#xD;
&#xD;
        xiv. Cardiac pacemaker, implantable cardioverter defibrillator, implantable infusion&#xD;
        device, or gastric electrical stimulator&#xD;
&#xD;
        xv. Orthostatic hypotension (defined as a drop of ≥ 20 mm Hg in systolic BP or a drop of ≥&#xD;
        10 mm Hg in diastolic BP when measured shortly after transitioning from lying down to&#xD;
        standing)&#xD;
&#xD;
        xvi. Any other condition which in the opinion of the investigator may adversely affect the&#xD;
        safety of the subject or would limit the subject's ability to complete the study&#xD;
&#xD;
        xvii. No smartphone/computer or limited access to a smartphone/computer&#xD;
&#xD;
        xviii. Regular use of any of the following medications or procedures: Medications that may&#xD;
        substantially affect intestinal motility, prokinetics at high doses (metoclopramide,&#xD;
        erythromycin, senna, prucalopride), anti-Parkinsonian medications, opiates, opioids,&#xD;
        calcium-channel blockers, enemas&#xD;
&#xD;
        xix. History of GI bleed within the last 3 months&#xD;
&#xD;
        xx. Pelvic floor dysfunction/defecatory disorder, based on subject history&#xD;
&#xD;
        xxi. Planning to undergo MRI during study time frame&#xD;
&#xD;
        xxii. Any known allergy to soybean or beeswax, or Calcium Carbonate&#xD;
&#xD;
        xxiii. Bradycardia less than 40 beats per minute&#xD;
&#xD;
        xxiv. Pain Disorder&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaimee Bruce, BSN</last_name>
    <phone>9185025145</phone>
    <email>JBruce@laureateinstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sahib Khalsa, MD</last_name>
    <phone>9185025743</phone>
    <email>skhalsa@laureateinstitute.org</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interoception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anorexia</mesh_term>
    <mesh_term>Anorexia Nervosa</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will upload the collected data via the NIMH Data Archive (NDA) data repository.</ipd_description>
    <ipd_time_frame>Data will be available approximately one year after the end of the study period.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

